Abstract 6462: Radiomics features of 18F-fluorodeoxyglucose positron-emission tomography as a novel prognostic signature in colorectal cancer

Background: The aim of this study was to investigate the prognostic value of radiomics signatures derived from 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography (PET) in patients with colorectal cancer (CRC). Methods: This was a retrospective, single-center study. From April 2008 to Jan 2014, we identified CRC patients who underwent 18F-FDG-PET before starting any neoadjuvant treatments and surgery. Radiomics features were extracted from the primary lesions identified on 18F-FDG-PET. Patients were divided into a training and a validation set by random sampling. A least absolute shrinkage and selection operator (LASSO) Cox regression model was applied for prognostic signature building with progression-free survival (PFS) using the training data set. Using the calculated radiomics score, a nomogram was developed, and the clinical utility of this nomogram was assessed in the validation set. Results: Three-hundred-and-eight-one patients with surgically resected CRC patients (training set 228 vs. validation set 153) were included. In the training set, a radiomics signature called a rad_score was generated using two PET-derived features such as Gray Level Run Length Matrix_Long-Run Emphasis (GLRLM_LRE) and Grey-Level Zone Length Matrix_Short-Zone Low Gray-level Emphasis (GLZLM_SZLGE). Patients with a high-rad_score in the training and the validation set had shorter PFS (P Conclusions: Textural features, such as GLRLM_LRE and GLZLM_SZLGE, derived from 18F-FDG-PET images may enable more detailed stratification of prognosis in patients with CRC. Citation Format: Jeonghyun Kang, Jean Rene Clemenceau, Sunho Park, Hongming Xu, Changjin Hong, Tae Hyun Hwang. Radiomics features of 18F-fluorodeoxyglucose positron-emission tomography as a novel prognostic signature in colorectal cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6462.